The effect of Melatonin on Improving the benign Prostatic Hyperplasia Urinary Symptoms, a Randomized Clinical Trial
Urology Journal,
Vol. 19 No. 05 (2022),
8 November 2022
,
Page 406-411
https://doi.org/10.22037/uj.v19i05.6761
Abstract
Purpose: to investigate the effect of melatonin along with tamsulosin in improving BPH urinary symptoms.
Materials and Methods: A total of 108 men with BPH symptoms, age of ≥ 50 years, and International Prostate
Symptom Score (IPSS) ≥ 8 entered into the parallel group randomized, double-blind clinical trial with balanced
randomization. The treatment group received of 3mg melatonin plus 0.4mg tamsulosin and the control group received placebo plus 0.4mg tamsulosin. Patients and physicians were concealed by sealed and opaque envelopes.
Symptoms were assessed at baseline and 1 month after treatment. Finally all scores at the initial and end of the
study were compared and analyzed using SPSS software.
Results: This study showed that adding melatonin to the classic treatment of BPH patients with tamsulosin could
significantly reduce the likelihood of nocturia by 2.39 times (95% CI: 1.07-5.32, OR = 2.39, p = 0.033) and could
also reduce the frequency of urination by 2.59 times (95% CI: 1.15-5.84, OR = 2.59, p = 0.021). There was no
statistically significant difference between the two groups in IPSS, intermittency, incomplete emptying, straining,
urgency, and weak stream.
Conclusion: Melatonin plus tamsulosin treatment is associated with a significant improvement of nocturia and
frequency in patients with benign proststic hyperplasia. However, it is necessary to do more studies.
- Benign prostatic hyperplasia, melatonin, tamsulosin, nocturia, frequency
How to Cite
References
2. Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Medicine Reviews. 2017;34:10-22.
3. Fathollahi A, Daneshgari F, Hanna-Mitchell AT. Melatonin and its role in lower urinary tract function: an article review. Current urology. 2014;8:113-8.
4. Tam CW, Chan KW, Liu VW, Pang B, Yao KM, Shiu SY. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. Journal of pineal research. 2008;45:403-12.
5. [No authorlisted]. Urological Sciences Research Foundation. International Prostate Symptom Score (IPSS). http://www.usrf.org/questionnaires/AUA_SymptomScore.html (Retrieved 10 March 2019).
6. [No authorlisted]. Tamsulosin Monograph for Professionals. https://www.drugs.com/monograph/tamsulosin.html (Retrieved 24 December 2019).
7. [No authorlisted]. Melatonin: Side Effects, Uses, Dosage (Kids/Adults). https://www.drugs.com/melatonin.html. (Retrieved 10 December 2019).
8. El-Adawy MS, Abdelaziz AY, Salem A, et al. Relation of baseline prostate volume to improvement of lower urinary tract symptoms due to tamsulosin monotherapy in benign prostatic hyperplasia: An exploratory, multicenter, prospective study. Urology Annals. 2020;12:271.
9. Song Y, Chen G, Huang P, Hu C, Liu X. Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. Frontiers in Pharmacology. 2020;11:763.
10. Kang TW, Chung HC. Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy. Therapeutic Advances in Urology. 2020;12:1756287220974130.
11. Fusco F, Creta M, Trama F, et al. Tamsulosin plus a new complementary and alternative medicine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a retrospective comparative study. Archivio Italiano di Urologia e Andrologia. 2020;92.
12. Matheson E, Hainer BL. Insomnia: pharmacologic therapy. American family physician. 2017;96:29-35.
13. [No authorlisted]. Circadin EPAR. European Medicines Agency (EMA). https://www.ema.europa.eu/en/documents/product-information/circadin-epar-product-information_en.pdf (Retrieved 31 May 2020).
14. Matsuta Y, Yusup A, Tanase K, Ishida H, Akino H, Yokoyama O. Melatonin increases bladder capacity via GABAergic system and decreases urine volume in rats. The Journal of urology. 2010;184:386-91.
15. Nomiya M, Burmeister DM, Sawada N, et al. Effect of melatonin on chronic bladder‐ischaemia‐associated changes in rat bladder function. BJU international. 2013;112:E221-E30.
16. Dobrek Ł, Thor P. The influence of melatonin and agomelatine on urodynamic parameters in experimental overactive bladder model: preliminary results. Postępy Higieny i Medycyny Doświadczalnej. 2011;65.
17. Dauchy RT, Hoffman AE, Wren-Dail MA, et al. Daytime blue light enhances the nighttime circadian melatonin inhibition of human prostate cancer growth. Comparative medicine. 2015;65:473-85.
18. Wang SW, Tai HC, Tang CH, et al. Melatonin impedes prostate cancer metastasis by suppressing MMP‐13 expression. Journal of Cellular Physiology. 2020.
19. Liu VWS, Yau WL, Tam CW, Yao K-M, Shiu SYW. Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-κB) activation and NF-κB activator-induced AR-V7 expression in prostate cancer cells: potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy. International journal of molecular sciences. 2017;18:1130.
20. Drake M, Mills I, Noble J. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. The Journal of urology. 2004;171:1199-202.
- Abstract Viewed: 1322 times
- 6761/pdf Downloaded: 670 times